UK halts hydroxychloroquine trials

Scientists in the UK halted trials of anti-malarial drug hydroxychloroquine on Friday (June 5)

after finding it "useless" at treating COVID-19 patients.

Martin Landray, an Oxford University professor, co-leading the RECOVERY trial, told reporters

"It doesn't work."

Results showed no significant difference in death rates after 28 days, in length of hospital stay or in other outcomes for patients either taking the drug or not.

U.S. President Donald Trump has hailed the drug as a potential "game changer" .

''I happen to be taking it. I happen to be taking it (several reporters overhead reacting) I'm taking it, hydroxychloroquine. Right now, yeah. A couple of weeks ago I started taking it, because I think it's good; I've heard a lot of good stories."

But controversy over its use grew

after a study published in medical journal The Lancet last month raised safety concerns.

The study was then retracted on Thursday after its authors said they were unsure about its data.

The World Health Organization is continuing its clinical trial of hydroxychloroquine pending a review.